RARB and neoplasm: Inactivation of the tumor suppressors RARB and CDKN2A was identified as crucial hallmark of tumor development and maintenance in distinct tumor types [12, 17] and loss of CDKN2A is expected to have a similar effect as loss of TP53 correlating with more aggressive tumors [17].